Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06441747
Title Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Australasian Gastro-Intestinal Trials Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS

Facility Status City State Zip Country Details
Chris O'Brien Lifehouse Camperdown New South Wales 2050 Australia Details
Monash Medical Centre Clayton New South Wales 3168 Australia Details
Westmead Hospital Westmead New South Wales 2145 Australia Details
Wollongong Hospital Wollongong New South Wales 2500 Australia Details
Royal Brisbane Women's Hospital Brisbane Queensland 4006 Australia Details
Princess Alexandra Hospital Woolloongabba Queensland 4102 Australia Details
Flinders Medical Centre Bedford Park South Australia Australia Details
Austin Health Melbourne Victoria 3084 Australia Details
Western Health Saint Albans Victoria 3021 Australia Details
St John of God Hospital, Subiaco Perth Western Australia Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field